A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Assess Efficacy, Safety and Tolerability of Orally Administered ERX1000 in Subjects With Obesity

Inclusion Criteria: 1. Able to comprehend and willing to sign an ICF and to abide by the study requirements. 2. Male and female subjects ages 18-60 years, inclusive. 3. BMI \>30 to \<50 kg/m2 4. Stable body weight for 3 months (self-reported loss/gain \<5%). 5. Stable diet and/or nutritional lifestyle for 3 months prior to randomization. 6. If a subject has current diagnosis of prediabetes, the following criteria must be met: 1. Hemoglobin A1c (HbA1c) ≤6.4% 2. Fasting glucose ≤125 mg/dL (≤6.94 mmol/L) 3. No history of ketoacidosis or hyperosmolar coma 7. Female subjects must not be…